Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.JPT Peptide Technologies (JPT) has collaborated with IUCT and LEITAT to jointly develop an enhanced anticancer therapy based on the biofocused targeting of nucleoside analogs linked to small cyclic peptidomimetics.
Subscribe to our email newsletter
The collaboration intends to create novel chemotherapeutic products exhibiting an enhanced safety and efficacy profile by selectively targeting inactive cytotoxic compounds toward tumor cells.
The deal makes use of JPT’s expertise in executing peptide based hit identification and IUCT’s and LEITAT’s expertise in biotechnological synthesis of nucleoside analogs and activity screening studies.
JPT managing director Holger Wenschuh said the previous scientific work at LEITAT and IUCT lays a solid basis to apply their peptide focused medicinal chemistry experience and capabilities to systematically amend physicochemical properties of the target compounds creating optimized functional profiles.
IUCT is an SME (Small and medium enterprise) focused on the development of new products and processes to be licensed to the pharmaceutical, chemical and biotechnological sector.
LEITAT Technological Center is a private research center which aims to provide solutions to the industry, adding value to both products and processes.